PERK activation preserves the viability and function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases

Yifeng Lin, Guangcun Huang, Stephanie Jamison, Jin Li, Heather P. Harding, David Ron, Wensheng Lin

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Remyelination occurs in multiple sclerosis (MS) lesions but is generally considered to be insufficient. One of the major challenges in MS research is to understand the causes of remyelination failure and to identify therapeutic targets that promote remyelination. Activation of pancreatic endoplasmic reticulum kinase (PERK) signaling in response to endoplasmic reticulum stress modulates cell viability and function under stressful conditions. There is evidence that PERK is activated in remyelinating oligodendrocytes in demyelinated lesions in both MS and its animal model, experimental autoimmune encephalomyelitis (EAE). In this study, we sought to determine the role of PERK signaling in remyelinating oligodendrocytes in MS and EAE using transgenic mice that allow temporally controlled activation of PERK signaling specifically in oligodendrocytes. We demonstrated that persistent PERK activation was not deleterious to myelinating oligodendrocytes in young, developing mice or to remyelinating oligodendrocytes in cuprizone-induced demyelinated lesions. We found that enhancing PERK activation, specifically in (re)myelinating oligodendrocytes, protected the cells and myelin against the detrimental effects of interferon-γ, a key proinflammatory cytokine in MS and EAE. More important, we showed that enhancing PERK activation in remyelinating oligodendrocytes at the recovery stage of EAE promoted cell survival and remyelination in EAE demyelinated lesions. Thus, our data provide direct evidence that PERK activation cell-autonomously enhances the survival and preserves function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases.

Original languageEnglish (US)
Pages (from-to)507-519
Number of pages13
JournalAmerican Journal of Pathology
Issue number2
StatePublished - Feb 2014

Bibliographical note

Funding Information:
Supported by National Multiple Sclerosis Society grants TA3026-A-1 and RG4813-A-2 (W.L.) and NIH grant NS073132 (W.L.). D.R. is a Principal Research Fellow of the Wellcome Trust.


Dive into the research topics of 'PERK activation preserves the viability and function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases'. Together they form a unique fingerprint.

Cite this